PLATI-PARP: A Phase 2 Study of Induction Docetaxel and Carboplatin Followed by Maintenance Rucaparib in Treatment of Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency
Latest Information Update: 03 Feb 2023
At a glance
- Drugs Carboplatin (Primary) ; Docetaxel (Primary) ; Rucaparib (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms PLATI-PARP
- 27 Jan 2023 Status changed from recruiting to active, no longer recruiting.
- 29 Apr 2022 Status changed from suspended to recruiting.
- 09 Feb 2022 Status changed from recruiting to suspended.